Skip to main content

The Future of Liquid Biopsies: Endless Possibilities for Cancer Testing

Liquid biopsies are poised to disrupt cancer testing as we know it. These novel blood tests analyze circulating tumor DNA (ctDNA) and other molecules released by cancer cells, providing a non-invasive option for detection, diagnosis, and monitoring. The promise of liquid biopsies has generated tremendous excitement, along with over $1 billion in investments and acquisitions in recent years. But how close are we to realizing their full potential? 




A recent review article sounds a note of caution amidst the hype. While liquid biopsies show ability to detect cancer, evidence that they improve patient outcomes is still lacking. Randomized trials with survival endpoints are needed to prove clinical utility. However, this provides the perfect opportunity for innovative diagnostics companies. Rather than dampening enthusiasm, these evidence gaps highlight major growth possibilities if companies can demonstrate real-world value.  

We envision liquid biopsies transforming oncology across three horizons:

Near-term: Expanding proven applications

Liquid biopsies are already endorsed to identify targetable mutations when tissue is insufficient. But less than 40% of early-stage lung cancers are detected. Improving sensitivity could expand use for therapy selection. Liquid biopsies have also shown promise to monitor minimal residual disease after surgery or reduce reliance on chemotherapy. Turning these proofs of concept into standard practice requires robust clinical validation and commercialization.  

Mid-term: Unlocking new applications

On the horizon are opportunities to diagnose suspected cancers, guide immunotherapy, and assess early response to chemotherapy. But questions remain about how liquid biopsies add value over current protocols. Innovative clinical trial designs are critical to integrate liquid biopsies into care pathways. Defining algorithms for follow-up of positive results can also increase utility. Further in the future, major investment will be needed to demonstrate liquid biopsies enable early detection and improve cancer mortality—the most disruptive possibility.  

Long-term: Enabling a revolution in cancer care

Ultimately, liquid biopsies’ ability for repeat, non-invasive sampling enables a fundamental shift to dynamic, personalized management based on the current state of a patient’s tumor. Regular liquid biopsies over the full course of disease can potentially track response, evolution, and emergence of resistance in real-time. This could replace the current paradigm of single static snapshots from tissue biopsies. Realizing this future requires building an entirely new liquid biopsy-centered oncology infrastructure.

Medicare Coverage is Critical to Unlock Liquid Biopsy Potential

As companies pursue this stepwise roadmap to transform cancer care with liquid biopsies, Medicare coverage and reimbursement will play a crucial role. Oncology is a Medicare-driven market, with over 60% of cancer care paid by the national health insurance program for seniors.


Unfortunately, coverage of liquid biopsies under Medicare has lagged behind their rapid technical development. Medicare coverage of liquid biopsy tests continues to evolve with limited coverage for the diagnosis of non-small cell lung cancer along with use in MRD. Many other uses of liquid biopsies are still considered investigational by payers.


Gaining Medicare coverage will require clinical studies producing real-world evidence of clinical utility and cost-effectiveness. Companies that engage with Medicare early and invest in pivotal trials designed to meet reviewers’ evidentiary standards will have an advantage. Initial coverage in limited patient populations can be expanded over time as new data emerges.


Proposed legislation like the Medicare Multi-Cancer Early Detection Screening Coverage Act also seeks to accelerate coverage for broad screening applications of liquid biopsies. However, many experts caution that major clinical unknowns remain which need to be addressed first.


In summary, intelligently designed clinical research and proactive payer engagement are instrumental for companies to unlock the full potential of liquid biopsies. Medicare coverage and payment remain key hurdles on the path to widespread adoption. Our firm brings deep expertise in clinical and coverage strategy to help clients navigate this dynamic landscape.


Let’s connect to explore how we can partner to drive access to your liquid biopsy assays and ensure coverage and reimbursement success!

Labels:

Comments

Post a Comment

Popular posts from this blog

Innovative Models for Lowering Drug Spending

Recently, much has been written about the escalating costs of drug prices in the US. Increasing drug prices are present challenges to those who struggle with affordability and access to their medications. The Inflation Reduction Act brought changes to the way the Medicare program reimburses for prescription drugs. Last year, President Biden challenged the Center for Medicare and Medicaid Innovation (CMMI) to develop and test new payment models that can support value-based payments and promote high-quality healthcare. CMMI has recently proposed three models intended to improve affordability and access to drugs as well as measuring the feasibility of implementation.       1. The Medicare High-Value Drug List Model Under this model, Part D plans would be encouraged to offer a low, fixed co-payment across all cost-sharing phases of the Part D drug benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients picking plans that participate in the Model wi
Post a Comment
Read more

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The
Post a Comment
Read more

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests. The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in id
Post a Comment
Read more